Lenvatinib Measures Up To Sorafenib In HCC But Prospects Limited?

Eisai's lenvatinib has hit its primary endpoint in a large Phase III trial comparing it with sorafenib in first-line hepatocellular carcinoma, paving the way for regulatory filings in the important indication and strengthening the firm's expansion strategy in oncology.